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Abstract Objective: Autosomal-recessive pyridox(am)ine
phosphate oxidase (PNPO) deficiency causes pyridoxal-5-
phosphate (PLP)-dependent epilepsy. We describe partial
PNPO deficiency with a transient response to pyridoxine (B6).
Methods: CSF neurotransmitter metabolites, PLP, and
amino acids were analyzed while the patient was receiving
pyridoxine. PNPO gene sequencing was performed by
standard techniques.
Results: A full-term 3,220 g male with refractory
neonatal seizures became seizure free for 6 weeks on
pyridoxine (B6). Breakthrough seizures followed. These
stopped upon the first dose of PLP although episodes
occurred as a dose became due. An unidentified peak was
detected on the chromatographic system used to measure
CSF PLP. PNPO gene sequencing identified a homozygous
mutation in a highly conserved area in exon 3: c.352G>A
p.G118R, predicting substitution of arginine for glycine.
At age 28 months the child has hypotonia and develop-
mental delay, both mild in severity.
Conclusions: Transient pyridoxine responsiveness may be
seen in partial PNPO deficiency. A CSF metabolite peak,
likely pyridoxine phosphate, is identifiable in patients with
PNPO deficiency who are taking supplemental pyridoxine.
Partial B6 responsiveness is an indication for possible PNPO
deficiency and trial of PLP.
Introduction
Pyridoxine (B6)-dependent epilepsy was first described
in 1954 (Hunt et al. 1954). The biological defect in this
syndrome was recently identified as antiquitin mutations
resulting in alpha aminoadipic semialdehyde (AASA)
dehydrogenase deficiency (Mills et al. 2006). This enzyme
is in the lysine degradation pathway and its deficiency leads
to accumulation of intermediates that include pipecolic
acid, AASA, and piperideine 60-carboxylate. The latter
sequesters pyridoxal 50-phophate (PLP), leading to PLP
deficiency within the central nervous system.
Pyridoxine (B6) is not itself an active cofactor. It is
converted, together with the pyridoxal and pyridoxamine
vitamers, to the active PLP via phosphorylation through the
action of a kinase followed by oxidation by pyridox(am)ine
50-phosphate oxidase (PNPO) (Surtees et al. 2006). Auto-
somal-recessive PNPO deficiency leads to a deficiency of
PLP and subsequently to PLP-dependent epilepsy that, in
general, is not thought to respond to pyridoxine (Mills et al.
2005). Without rapid detection and specific intervention,
this causes catastrophic neonatal encephalopathy. In this
report, we describe partial PNPO deficiency in an infant
initially suspected to have pyridoxine responsiveness.
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CSF neurotransmitter metabolites, pyridoxal-5-phosphate,
and amino acid quantification. PNPO gene sequencing was
performed by standard techniques on the proband followed
by the parents.
Results
A full-term 3,220 g newborn male delivered following an
uncomplicated gestational course and maternal labor presented
with irritability, inconsolable crying, erratic eye movements
with eyelid twitching, and grunting sounds 12 h following
birth. EEG showed bilateral sharp discharges and episodic
background suppression, although without a constant temporal
correlation with the clinical symptoms. MRI was unremark-
able. Following trials of phenobarbital and levetiracetam, the
patient became seizure free for 6 weeks on pyridoxine.
Breakthrough tonic seizures then occurred at 3.5 months of
age, followed bymyoclonic seizures, leading to hospitalization
and trials of topiramate and prednisolone which were ineffec-
tive. EEG monitoring showed intermittent paroxysms of
diffuse sharp electrographic activity associated variably with
clinical facial grimacing, abnormal eyemovements, and erratic
multifocal myoclonias of the extremities which sometimes
resembled thrashing type movements (Fig. 1). These were
separated by periods of relative background suppression,
accompanied by an initial tonic spasm and then quieting until
the next paroxysm. This sequence persisted 25 min until
intravenous lorazepam administration led to temporary
resolution. The seizures stopped upon the first dose of PLP,
but breakthrough events occurred as a dose became due. The
patient achieved complete seizure control on PLP 10 mg/kg/
dose given every 6 h.
CSF was sent for neurotransmitter metabolites, PLP, and
amino acid analysis during the patient’s hospitalization with
concomitant pyridoxine therapy. CSF PLP level was 23
nmol/L (normal range of 23–64 nmol/L). CSF amino acids
showed a slight increase in threonine. Neurotransmitter
metabolites were normal. An additional, previously uniden-
tified, peak was detected on the chromatographic system
used to measure PLP.
Subsequent PNPO gene sequencing identified a homo-
zygous mutation in a highly conserved area in exon 3:
c.352G>A p.G118R, predicting a substitution of arginine
for glycine. Both parents were identified as heterozygous
for this mutation. The patient has had sustained seizure
control and developmental progress with ongoing dosing of
PLP 10 mg/kg/dose administered four times daily with
follow-up out to 2 years of age. Breakthrough clinical
events tend to appear with intervals approaching 7–8 h after
a prior dose, and examination shows mild symmetrical
hypotonia and language delay. Developmental assessment
at age 28 months indicated these levels: gross motor 21–24
months, fine motor 20–22 months, cognitive 20 months
with scatter to 27 months, social-emotional 21–24 months,
receptive language 24–28 months, expressive language
20–23 months, and self-help skills 21–24 months. His
overall vocabulary is approximately 40 words, with the
ability to place a few words together. However, much of his
speech is repetition.
Discussion
The neonatal onset neurotransmitter disorders include both
pyridoxine and PLP-responsive epilepsies (Pearl 2009).
PLP, the biologically active form of B6, is a cofactor in
approximately 120 enzymatic reactions, many of which
involve amino acid and neurotransmitter metabolic path-
ways (Stockler et al. 2011). PNPO deficiency represents an
epileptic encephalopathy resistant to pyridoxine but respon-
sive to PLP.
The PNPO mutation identified, c.352G>A, has not been
reported before. It is predicted by Polyphen to be probably
damaging and by SIFT to be damaging. Our proband
demonstrated an initial response in seizure control to oral
pyridoxine dosing following refractoriness to standard
antiepileptic drugs. When this control was lost after 6 weeks,
CSF analysis was undertaken for neurotransmitter metabolite
and PLP analysis. An unidentified compound was detected
on the fluorescence chromatogram which has been noted in
other patients with PNPO deficiency supplemented with
pyridoxine. This peak is not detected in CSF samples derived
from individuals with alpha-AASA dehydrogenase defi-
ciency while on pyridoxine supplementation and is not the
same peak seen in the chromatograms of folinic acid-
responsive patients. We suspect this represents pyridoxine
phosphate as this compound has been shown to accumulate
in plasma in the absence of the PNPO (Footitt et al. 2012).
The seizure semiology in our patient is notably similar to
the recently reported signs in four patients with pyridoxine-
responsive epilepsy and one patient with PNPO deficiency
(Schmitt et al. 2010). The features of neonatal and infantile
irritability, inconsolable crying, facial grimacing, abnormal
eye movements, eye twitching, multifocal myoclonias and
erratic movements, and tonic seizures are characteristic of
both diagnoses. The intermittent periods of EEG back-
ground suppression in our patient are remarkably similar to
the PNPO-deficient patient in that series, as is the clinical
observation of breakthrough events approximately 7 h after
the last dose of PLP. The inconstant ictal EEG findings,
absence of consistent clinical correlation with otherwise
nonspecific paroxysmal EEG changes, and difficulty
distinguishing interictal from ictal EEG background
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reported in both pyridoxine-responsive epilepsy and PNPO
deficiency were also seen in our patient.
Patients without a defect in PNPO who receive pyridox-
ine generally have high-normal to above normal CSF PLP
levels (KH – personal observation). The borderline low
CSF PLP seen in our patient, while on pyridoxine, may
indicate that the c.352G>A p.G118R mutation is “leaky”
and allows for some oxidation of pyridoxine phosphate.
This may explain the partial clinical response to pyridoxine.
The pyridoxine dose was not increased, and it is plausible
that a static pyridoxine dose was not sufficient to maintain
efficacy as the child grew. Enzyme studies of the expressed
mutant protein would be required to verify this hypothesis.
Our patient demonstrates that an initial response to
pyridoxine that fails to materialize into permanent seizure
control may be an indication of an underlying PNPO
deficiency. In this situation, a trial with pyridoxal-5-
phosphate is warranted.
Synopsis
We describe a novel case of partial pyridox(am)ine
phosphate oxidase (PNPO) deficiency and pyridoxal-5-
phosphate-dependent epilepsy with a transient response to
pyridoxine (B6) treatment.
Fig. 1 EEG of patient with PNPO deficiency, age 5 months, showing
paroxysms of diffuse spike-wave discharges accompanied by multifo-
cal myoclonic and erratic movements. Settings: 20 s epoch, sens 10
uV/mL, tc 0.1 s, HFF 70 Hz (Reproduced with permission from
Alduligan and Pearl 2012)
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